Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)
摘要:
C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors. The introduction of a CS methyl group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well. Exploration of C8-substitutions led to the identification of the bromo derivative as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors. Structure activity studies on the C8-bromo derivatives ultimately led to the discovery of clinical candidate 29 (BI 201335), a very potent and selective inhibitor of genotypel NS3 protease with a promising PK profile in rats.
Macrocyclic peptides active against the hepatitis C virus
申请人:Llinas-Brunet Montse
公开号:US20050080005A1
公开(公告)日:2005-04-14
Compounds of formula I:
wherein D, R
4
, R
3
, L
0
, L
1
, L
2
, R
2
and R
c
are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Compounds of formula (I):
wherein B, X, R
3
, L
0
, L
1
, L
2
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS
申请人:LLINAS-BRUNET Montse
公开号:US20100028300A1
公开(公告)日:2010-02-04
Compounds of formula I:
wherein D, R
4
, R
3
, L
0
, L
1
, L
2
, R
2
and R
C
are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.